i
www.nature.com/scientificreports/
49.Rosenberg,B.,Vancamp,L.&Krigas,T.InhibitionofCellDivisioninEscherichiaColibyElectrolysisProductsfromaPlatinum
Electrode.Nature.205,698–699(1965).
50.Kang,Y.H.,Lee,K.A.,Kim,J.H.,Park,S.G.&Yoon,D.Y.MitomycinCmodulatesDNA-doublestrandbreakrepairgenesin
cervicalcarcinomacells.AminoAcids.39,1291–1298,doi:10.1007/s00726-010-0568-5(2010).
51.Schmittgen,T.D.,Wientjes,M.G.,Badalament,R.A.&Au,J.L.PharmacodynamicsofmitomycinCinculturedhumanbladder
tumors.CancerRes.51,3849–3856(1991).
52.Tolley,D.A.etal.TheeffectofintravesicalmitomycinConrecurrenceofnewlydiagnosedsuperficialbladdercancer:afurther
reportwith7yearsoffollowup.JUrol.155,1233–1238(1996).
53.Xu,L.etal.EpirubicinenhancesTRAIL-inducedapoptosisingastriccancercellsbypromotingdeathreceptorclusteringinlipid
rafts.MolMedReport.4,407–411,doi:10.3892/mmr.2011.439(2011).
54.Kuroda,M.,Niijima,T.,Kotake,T.,Akaza,H.&Hinotsu,S.Effectofprophylactictreatmentwithintravesicalepirubicinon
recurrenceofsuperficialbladdercancer–The6thTrialoftheJapaneseUrologicalCancerResearchGroup(JUCRG):arandomized
trialofintravesicalepirubicinatdoseof20mg/40ml,30mg/40ml,40mg/40ml.EurUrol.45,600–605,doi:10.1016/j.
eururo.2003.12.010(2004).
55.Meisner,L.F.,Wu,S.Q.,Christian,B.J.&Reznikoff,C.A.Cytogeneticinstabilitywithbalancedchromosomechangesinan
SV40transformedhumanuroepithelialcellline.Cancerresearch.48,3215–3220(1988).
56.Redwood,S.M.,Liu,B.C.,Weiss,R.E.,Hodge,D.E.&Droller,M.J.Abrogationoftheinvasionofhumanbladdertumorcells
byusingproteaseinhibitor(s).Cancer.69,1212–1219(1992).
57.Xu,B.etal.Explorationofthecorrelationsbetweeninterferon-gammainpatientserumandHEPACAMinbladdertransitional
cellcarcinoma,andtheinterferon-gammamechanisminhibitingBIU-87proliferation.TheJournalofurology.188,1346–1353,
doi:10.1016/j.juro.2012.06.005(2012).
58.Li,J.etal.Areviewonvarioustargetedanticancertherapies.TargetOncol.7,69–85,doi:10.1007/s11523-012-0212-2(2012).
59.Heiser,L.M.etal.Subtypeandpathwayspecificresponsestoanticancercompoundsinbreastcancer.ProcNatlAcadSciUSA.
109,2724–2729,doi:10.1073/pnas.1018854108(2012).
60.Andrisano,V.,Bartolini,M.,Gotti,R.,Cavrini,V.&Felix,G.Determinationofinhibitors’potency(IC50)byadirecthigh-
performanceliquidchromatographicmethodonanimmobilisedacetylcholinesterasecolumn.JChromatogrBBiomedSciAppl.
753,375–383(2001).
61.El‐Sheikh,A.etal.InhibitionofAuroraKinaseAenhanceschemosensitivityofmedulloblastomacelllines.Pediatricblood&
cancer.55,35–41(2010).
62.Ohashi,K.etal.Sustainedsurvivalofhumanhepatocytesinmice:AmodelforinvivoinfectionwithhumanhepatitisBand
hepatitisdeltaviruses.NatMed.6,327–331,doi:10.1038/73187(2000).
Acknowledgements
ThisworkwassupportedbytheNationalNaturalScienceFoundationofChina(8147263830921140312,
81301293and81272289)andAnhuiScienceFoundation(1508085QH183and1508085QH178)
AuthorContributions
Studydesign:J.Z.,C.H.,Q.W.;Manuscriptdrafting:J.Z.,Q.L,M.S,C.H.,X.D.(themathematicpart);
Experimentation:Q.L.,C.Z.,X.D.,H.D.,D.Z.,W.C.,H.X.,Y.W.,W.X.,L.L.,H.Z.andY.H.
AdditionalInformation
Supplementaryinformationaccompaniesthispaperathttp://www.nature.com/srep
Competingfinancialinterests:Theauthorsdeclarenocompetingfinancialinterests.
Howtocitethisarticle:Liu,Q.etal.Preclinicaloptimizationofabroad-spectrumanti-bladdercancer
tri-drugregimenviatheFeedbackSystemControl(FSC)platform.Sci.Rep.5,11464;doi:10.1038/
srep11464(2015).
ThisworkislicensedunderaCreativeCommonsAttribution4.0InternationalLicense.The
imagesorotherthirdpartymaterialinthisarticleareincludedinthearticle’sCreativeCom-
monslicense,unlessindicatedotherwiseinthecreditline;ifthematerialisnotincludedunderthe
CreativeCommonslicense,userswillneedtoobtainpermissionfromthelicenseholdertoreproduce
thematerial.Toviewacopyofthislicense,visithttp://creativecommons.org/licenses/by/4.0/
ScientificRepoRts|5:11464|DO:10.1038/srep1146417 |
|
